Back to Trades
Total Value
$11.3M
Filing Date
Jul 23, 2026
1 transactions
Trade Summary
On Jul 21, 2026, Parikh Anand Kiran, Insider, reported $11.3M of Faeth Therapeutics, Inc. (FTH) across 1 transactions. The filing covers company securities and reflects balanced net activity of $0. Reported prices ranged from $28.37. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.
Company Information
- Company Name
- Faeth Therapeutics, Inc.
- Ticker Symbol
- FTH
- CIK
- 0001829802
Insider Information
- Role
- Insider
- Location
- AUSTIN, TX
Filing Details
- Filing Date
- Jul 23, 2026
- Transaction Date
- Jul 21, 2026
- Accession Number
- 0002111813-26-000012
- Form Type
- 4
Derivative Transactions
| Date | Security | Shares | Exercise Price | Type | Value |
|---|---|---|---|---|---|
| Jul 21, 2026 | FTH derivative | 398,018 | $28.37 | Grant/Award | $11.3M |
Want live alerts when Parikh Anand Kiran trades again?
Download Insider Trades to track FTH, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.
Footnotes
- (F1)Represents a performance-based stock option that becomes exercisable, if at all, on the later of (i) the first date on which the average closing price of the Issuer's common stock on the Nasdaq Stock Market over any 30 consecutive calendar-day period equals or exceeds $70.00 (the "Stock Price Hurdle") and (ii) the first anniversary of the date of grant, in each case subject to the Reporting Person's continued service with the Issuer as of each such date. If the Stock Price Hurdle is not achieved by the fourth anniversary of the date of grant (the "Performance Period"), the option will be forfeited in its entirety.
- (F2)In the event of a Change in Control (as defined in the Issuer's 2026 Equity Incentive Plan) of the Issuer prior to the end of the Performance Period, the Stock Price Hurdle will be deemed achieved if the per-share consideration payable in the transaction equals or exceeds $70.00 (subject to equitable adjustment). If so deemed achieved, the option will vest in full immediately prior to the consummation of the Change in Control, subject to the Reporting Person's continued service with the Issuer through such time. If the Stock Price Hurdle is not achieved or deemed achieved in connection with the Change in Control, the option will be forfeited in its entirety.